Last reviewed · How we verify
NCT05700565: PRIA
Treatment of Immune-related Adverse Events Refractory to Standard Therapy and Associated Changes in Immunophenotype
trial testing Extracorporeal photopheresis in Immune-related Adverse Event in 50 participants. Currently enrolling.
1 January 2027
Quick facts
| Lead sponsor | Lucie Heinzerling |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 1 January 2022 |
| Primary completion | 1 January 2027 |
| Estimated completion | 1 January 2027 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- Extracorporeal photopheresis — full drug profile →
- Other immunosuppressive or immunomodulatory drugs
Conditions studied
- Immune-related Adverse Event — all drugs for Immune-related Adverse Event →
Sponsor
Lucie Heinzerling
Who can join
Eligibility, any sex, with Immune-related Adverse Event. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is an open, monocentric study. It includes patients with irAE refractory to standard therapy or patients where corticosteroids cannot be tapered. Patients will either be treated with ECP or second line immunosuppressive therapy according to investigator's choice. Patients will be followed for 24 weeks after first treatment.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Extracorporeal photopheresis vs. systemic immunosuppression for immune-related adverse events: Interim analysis of a prospective two-arm study.
Ertl C, Ruf T, Hammann L, Piseddu I, et al · · 2024 · cited 9× · PMID 39383612 · DOI 10.1016/j.ejca.2024.115049 -
Adiponectin to the rescue: extracorporeal photopheresis for managing immune checkpoint inhibitor-induced toxicities.
Reschke R, Enk AH, Hassel JC. · · 2025 · cited 1× · PMID 40210856 · DOI 10.1038/s41392-025-02205-y -
Evidence for optimal treatment of immune-related adverse events needed - should we use extracorporeal photopheresis?
Heinzerling L. · · 2025 · PMID 40351120 · DOI 10.1080/1750743x.2025.2498316
Verify or expand the search:
- PubMed search for NCT05700565
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Extracorporeal photopheresis
Trials testing the same drug.
- NCT05052385 — ECP Combination Study · completed
- NCT05882331 — Extracorporeal Photopheresis as a Possible Therapeutic Approach to Adults With Severe and Critical COVID-19 · NA · completed
- NCT03583229 — Coronary Artery Disease After Heart Transplantation · NA · unknown
- NCT03124056 — Clinical and Biomarker Study of the Efficacy of Extracorporeal Photopheresis in Graft-versus-host Disease · completed
- NCT04792294 — Multicenter Analysis of Efficacy and Outcomes of Extracorporeal Photopheresis as Treatment of Chronic Lung Allograft Dys · unknown
Other recruiting trials for Immune-related Adverse Event
Currently open trials in the same condition.
- NCT06860542 — Inhaled Budesonide for REcurrence Prevention and Adjuvant THerapy in Checkpoint Inhibitor Pneumonitis · Phase 2 · recruiting
- NCT06613165 — Exploring the Treatment Duration of PD-1 Neoadjuvant Therapy in Stage II-III dMMR Rectal Cancer · recruiting
- NCT06278857 — SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr) · Phase 2 · recruiting
- NCT06702566 — The Effect of Serum Ferritin in irAE · NA · recruiting
- NCT05832606 — Food Intervention to Reduce Immunotherapy ToXicity · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05700565 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Lucie Heinzerling
- Last refreshed: 15 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05700565.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing